A multi-center, double-blind, randomized, placebo-controlled study of orally administered SP01A for 28 days as monotherapy treatment in HIV-infected patients with evidence of resistance to currently available antiretroviral therapy

Trial Profile

A multi-center, double-blind, randomized, placebo-controlled study of orally administered SP01A for 28 days as monotherapy treatment in HIV-infected patients with evidence of resistance to currently available antiretroviral therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2007

At a glance

  • Drugs Procaine (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors Samaritan Pharmaceuticals
  • Most Recent Events

    • 01 Nov 2006 Status change
    • 24 Jan 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top